$109.54
Price
$11.0B
Market Cap
19.7
P/E Ratio
16.9
Forward P/E
$5.55
EPS (TTM)
0.69%
Dividend Yield
$72M
Cash
$2.7B
Total Debt
100M
Shares Out
$92.53
$127.99
52-Week Range
Institutional Ownership of ENCOMPASS HEALTH CORP
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for ENCOMPASS HEALTH CORP
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q3 | |||||
| SELL | -12.0% | 50.7K | $6M | $120.22 | |
| 2025-Q2 | |||||
| SELL | -18.7% | 57.6K | $7M | $118.61 | |
| 2025-Q1 | |||||
| SELL | -13.3% | 70.8K | $7M | $98.60 | |
| 2024-Q4 | |||||
| SELL | -11.4% | 81.7K | $8M | $98.66 | |
| 2024-Q3 | |||||
| SELL | -2.3% | 92.2K | $9M | $90.64 | |
| 2024-Q2 | |||||
| SELL | -6.1% | 94.4K | $8M | $84.50 | |
| 2024-Q1 | |||||
| SELL | -4.7% | 100.5K | $8M | $73.55 | |
| 2023-Q3 | |||||
| SELL | -14.0% | 105.5K | $7M | $69.09 | |
| 2023-Q2 | |||||
| SELL | -3.1% | 122.7K | $8M | $62.30 | |
| 2022-Q4 | |||||
| SELL | EXIT | — | — | $56.00 | |
| SELL | -4.8% | 126.7K | $8M | $56.00 | |
| 2022-Q2 | |||||
| SELL | -1.7% | 3.0M | $165M | $51.59 | |
| BUY | +5.2% | 133.0K | $7M | $51.59 | |
| 2022-Q1 | |||||
| BUY | +318.9% | 3.0M | $213M | $52.43 | |
| BUY | +27.4% | 126.5K | $9M | $52.43 | |
| 2021-Q4 | |||||
| BUY | NEW | 716.1K | $47M | $50.83 | |
| BUY | +10.1% | 99.2K | $6M | $50.83 | |
| 2021-Q3 | |||||
| BUY | +44.1% | 90.2K | $7M | $63.23 | |
| 2021-Q2 | |||||
| BUY | +8.7% | 62.6K | $5M | $67.27 | |
| 2021-Q1 | |||||
| SELL | EXIT | — | — | $65.25 | |
| BUY | +40.4% | 57.5K | $5M | $65.25 | |
| 2020-Q4 | |||||
| SELL | -20.3% | 2.6M | $219M | $57.31 | |
| BUY | +12.2% | 41.0K | $3M | $57.31 | |
| 2020-Q3 | |||||
| BUY | +23.8% | 3.3M | $215M | $51.63 | |
| BUY | +34.9% | 36.5K | $2M | $51.63 | |
| 2020-Q2 | |||||
| BUY | +85.2% | 2.7M | $166M | $53.98 | |
| BUY | +19.2% | 27.1K | $2M | $53.98 | |
| 2020-Q1 | |||||
| BUY | NEW | 1.4M | $93M | $61.38 | |
| SELL | -10.3% | 22.7K | $1M | $61.38 | |
| 2019-Q4 | |||||
| BUY | +2.5% | 25.3K | $2M | $55.31 | |
| 2019-Q3 | |||||
| BUY | +12.8% | 24.7K | $2M | $50.29 | |
| 2019-Q2 | |||||
| BUY | +7.9% | 21.9K | $1M | $48.33 | |
| 2019-Q1 | |||||
| BUY | +18.6% | 20.3K | $1M | $51.72 | |
| 2018-Q4 | |||||
| BUY | +16.3% | 17.1K | $1M | $57.56 | |
| 2018-Q3 | |||||
| SELL | -8.0% | 14.7K | $1M | $62.23 | |
| 2018-Q1 | |||||
| BUY | +4.6% | 16.0K | $915000 | $42.18 | |
Insider Trading for ENCOMPASS HEALTH CORP
6 Months Insider Sentiment
Buy $0
Sell $0
0
Buys
0
Sells
+0
Net
10
Grants
Largest
$35K
Reidy
$27K
III
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | Christopher R Reidy | Director | GRANT | 16 | — | — |
| Oct 15, 2025 | Christopher R Reidy | Director | GRANT | 288 | $123.23 | $35K |
| Oct 15, 2025 | Edward M Christie III | Director | GRANT | 7 | — | — |
| Oct 15, 2025 | Edward M Christie III | Director | GRANT | 223 | $123.21 | $27K |
| Oct 15, 2025 | Greg D Carmichael | Director | GRANT | 23 | — | — |
| Oct 15, 2025 | Joan E Herman | Director | GRANT | 73 | — | — |
| Oct 15, 2025 | Kevin J. O'Connor | Director | GRANT | 14 | — | — |
| Oct 15, 2025 | Leslye G Katz | Director | GRANT | 73 | — | — |
| Oct 15, 2025 | Nancy M Schlichting | Director | GRANT | 33 | — | — |
| Oct 15, 2025 | Terrance Williams | Director | GRANT | 23 | — | — |